A Phase 1 Non-randomized/2 Randomized Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients With Hematologic Malignancies

Trial Profile

A Phase 1 Non-randomized/2 Randomized Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients With Hematologic Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Programmed cellular immunotherapeutic (Primary)
  • Indications Cytomegalovirus infections; Graft-versus-host disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 21 Dec 2017 According to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology, phase 1 portion of PROTECT is projected to enroll 6-10 subjects and by the 2017 ASH meeting, enrollment will be complete with at least six subjects projected to have reached Day 100+, and the safety and efficacy results will be updated.
    • 12 Dec 2017 Results (n=5) assessing safety and efficacy data of protmune (ex vivo programmed mobilized peripheral blood cells) for allogeneic hematopoietic cell transplantation in adult patients with hematologic malignancies, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Dec 2017 According to a Fate Therapeutics media release, day 100 results from the phase I portion of this trial (n = 7) were presented at the 59th American Society of Hematology Annual Meeting and Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top